The New P&L speaks to Emma Chaffin, Vice President & Country Head of biotechnology company Galapagos UK

This week, The New P&L – Principles & Leadership in Business podcast series speaks to Emma Chaffin, Vice President & Country Head, of biotech innovator, Galapagos UK, a clinical-stage biotechnology company, specialising in the discovery and development of small molecule medicines with novel modes of action. Galapagos has an ambition to become a leading global biopharmaceutical company, focused on the discovery, development and commercialisation of innovative medicines that will improve people's lives. We discuss with Emma how to ensure a free-thinking innovation process remains accountable and in line with the strategic vision of a company; the critical role of collaboration and partnerships in the development of the Covid-19 vaccines and what this means for the future of R&D, including what leadership lessons can be learned; as well as what the convergence of the bioscience, health, and big tech sectors will mean for the future of research, innovation and data privacy. If you would like to learn more about Galapagos, please go to: https://www.glpg.com/ To join The New P&L movement go to: www.principlesandleadership.com and subscribe. Join our Instagram community: @principlesandleadership